Fujian Cancer Hospital, Fujian Medical University
Welcome,         Profile    Billing    Logout  
 2 Trials 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
huang, weiwei
FS-1502-III1-01, NCT05755048: FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

Recruiting
3
314
RoW
Investigational drug: Recombinant Anti-HER2 Humanized Monoclonal Antibody - Monomethyl Auristatin F Conjugates for Injection (FS-1502), Control drug: Trastuzumab emtansine (Kadcyla, T-DM1)
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Breast Cancer
07/25
01/26
NCT05860465: Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer

Recruiting
2/3
254
RoW
SPH4336 Tablets, SPH4336 Tablets Placebo
Shanghai Pharmaceuticals Holding Co., Ltd
Locally Advanced or Metastatic Breast Cancer
12/25
12/25
Arise-FJ-B02, NCT05019690: Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer

Recruiting
1/2
29
RoW
Apatinib Mesylate, apatinib, Albumin-Bound Paclitaxel, albumin paclitaxel
Fujian Cancer Hospital
Advanced Triple Negative Breast Cancer
12/24
06/25
HEROIC, NCT06551220: Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer with Different HER2 Expression Patterns

Recruiting
N/A
800
RoW
Trastuzumab Deruxtecan
Sun Yat-sen University
Metastatic Breast Cancer
01/25
01/25
ERI-Based-01, NCT05953909: A Study of Eribulin-Based Regimen Versus Other Chemotherpy in Triple-Negative Metastatic Breast Cancer ().

Active, not recruiting
N/A
120
RoW
Eribulin-Based Regimen, Not Applicable since observational study, nab-paclitaxel based regimen, Other Chemotherapy Regimen
Fujian Cancer Hospital
Breast Cancer
08/23
08/23
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
huang, weiwei
FS-1502-III1-01, NCT05755048: FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

Recruiting
3
314
RoW
Investigational drug: Recombinant Anti-HER2 Humanized Monoclonal Antibody - Monomethyl Auristatin F Conjugates for Injection (FS-1502), Control drug: Trastuzumab emtansine (Kadcyla, T-DM1)
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Breast Cancer
07/25
01/26
NCT05860465: Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer

Recruiting
2/3
254
RoW
SPH4336 Tablets, SPH4336 Tablets Placebo
Shanghai Pharmaceuticals Holding Co., Ltd
Locally Advanced or Metastatic Breast Cancer
12/25
12/25
Arise-FJ-B02, NCT05019690: Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer

Recruiting
1/2
29
RoW
Apatinib Mesylate, apatinib, Albumin-Bound Paclitaxel, albumin paclitaxel
Fujian Cancer Hospital
Advanced Triple Negative Breast Cancer
12/24
06/25
HEROIC, NCT06551220: Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer with Different HER2 Expression Patterns

Recruiting
N/A
800
RoW
Trastuzumab Deruxtecan
Sun Yat-sen University
Metastatic Breast Cancer
01/25
01/25
ERI-Based-01, NCT05953909: A Study of Eribulin-Based Regimen Versus Other Chemotherpy in Triple-Negative Metastatic Breast Cancer ().

Active, not recruiting
N/A
120
RoW
Eribulin-Based Regimen, Not Applicable since observational study, nab-paclitaxel based regimen, Other Chemotherapy Regimen
Fujian Cancer Hospital
Breast Cancer
08/23
08/23

Download Options